Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Finished Dosage Form Business and Assets of Xellia Pharmaceuticals for approximately $190 million on June 17, 2024. A cash consideration of $135 million will be paid by Hikma Pharmaceuticals PLC and an additional contingent consideration of up to $50 million cash, subject to the achievement of certain regulatory and commercial milestones. As a part of transaction, US finished dosage form business and assets, including a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and an R&D center in Zagreb, Croatia will be acquired.